Cerebral Artery Syndrome Treatment Market Size & Share, by Treatment (Surgery, Medication); Surgery Type (Carotid Endarterectomy, Angioplasty, Bypass Surgery); Distribution Channel (Hospital, Specialty Clinic, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3463
  • Published Date: Jan 01, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Cerebral Artery Syndrome Treatment Market size is anticipated to cross USD 5 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of cerebral artery syndrome treatment was over USD 2 Billion. The rising incidences of cerebral artery syndrome are a major driver for the growth of the market. Cerebral artery syndrome is a major health problem that affects millions of people worldwide, and it is a leading cause of disability globally. As the population ages and risk factors such as hypertension, diabetes, and smoking become more prevalent, the number of people affected by cerebral artery syndrome is on the rise. For instance, an estimated 1.28 billion persons globally between the ages of 30 and 79 suffer from hypertension, with the majority (two thirds) residing in low- and middle-income nations. This increased prevalence creates a higher demand for effective treatment options.

Furthermore, the rising number of stroke patients is driving the demand for effective stroke treatment options, including medications, medical devices, and rehabilitation therapies. Pharmaceutical companies are investing in developing new stroke treatments, which is also driving the market's growth. In addition, rehabilitation centers are expanding their services to meet the needs of stroke patients, offering a range of therapies to help patients recover and regain their independence.


Cerebral Artery Syndrome Treatment Market
Get more information on this report: Request Free Sample PDF

Cerebral Artery Syndrome Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Research and Development Activities - The advancement of cerebral artery syndrome treatment is greatly aided by research and development efforts. Researchers are always looking into new ways to treat cerebral artery syndromes, like targeted drug delivery systems, gene therapy, and stem cell therapy. These approaches have the potential to completely change the way that the condition is treated. Research has a crucial role in determining how the market for cerebral artery syndrome treatments will develop in the future by promoting improvements in care and therapy. For instance, using a novel approach to preclinical animal testing, researchers have identified uric acid as a potential therapy to enhance recovery from acute ischemic stroke using a new method for conducting preclinical animal research. In the study, researchers from the National Institutes of Health’s Stroke Preclinical Assessment Network (SPAN) rigorously tested the effectiveness of six novel therapies in reducing ischemic brain injury in rodents using strategies normally reserved for clinical studies in humans.
  • Growing Technological Advancements in Healthcare Industry - Advances in imaging technology, including computed tomography (CT), magnetic resonance imaging (MRI), and other imaging modalities, have made cerebral artery syndrome diagnosis and therapy more accurate. As per a report, approximately 5.8,000 magnetic resonance imaging (MRI) machines were in operation globally in 2021. Also, it has been predicted that by 2030, there will be more than 10,000 MRI units worldwide. These medical imaging technologies enable physicians to precisely and thoroughly visualize the brain and blood arteries, assisting them in determining the precise location, scope, and severity of the ailment. Treatment plans might be more focused and successful when an accurate diagnosis is made. Considering all this, the cerebral artery syndrome treatment market is anticipated to grow significantly in the upcoming years.  
  • Growing Awareness among the Individuals regarding the Cerebral Artery Syndrome - Increasing awareness about cerebral artery syndrome and improved diagnostics techniques have also contributed to market growth. Also, public health campaigns are playing a major role in spreading awareness about the signs and symptoms of strokes. Further, social media platforms are helping to educate individuals about strokes and their prevention in the early stages. Therefore, these factors are propelling the growth of the market.

Challenges

  • High Cost Associated with the Treatment - Advanced therapies and procedures, such as neurointerventional techniques can be expensive, limiting access to these treatments for some patients. Affordability and accessibility are important factors in ensuring that all individuals with cerebral artery syndrome have access to appropriate care. Also, the cost of the treatment can go from USD 27,473 to USD 70,601, which is quite expensive for most patients. Therefore, the high cost may hinder the expansion of the cerebral artery syndrome treatment market.
  • Limited Accessibility to Reversal Agents for Anticoagulants may hamper the Growth of the Market.
  • Severe Side Effects of some Drugs and Treatments may Hinder the Growth of the Market.

Cerebral Artery Syndrome Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~ 6%

Base Year Market Size (2023)

~ USD 2 Billion

Forecast Year Market Size (2036)

~ USD 5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Cerebral Artery Syndrome Treatment Segmentation

Surgery Type (Carotid Endarterectomy, Angioplasty, Bypass Surgery)

Cerebral artery syndrome treatment market for the carotid endarterectomy segment is anticipated to hold the largest share of 43% during the forecast period. As it lowers the risk of stroke, carotid endarterectomy is a surgical technique that is becoming more and more common. Therefore, the increasing number of cases of stroke is propelling the growth of the segment. The high success rate of this method is the primary cause of the tremendous growth. Additionally, this sort of surgery is widely accessible, which promotes the growth of this market. The procedure's increased demand has also been attributed to improvements in safety and effectiveness brought about by medical technological breakthroughs.

Distribution Channel (Hospital, Specialty Clinic, Online Pharmacies)

The hospital segment in the cerebral artery syndrome treatment market is expected to hold a share of 50% during the foreseen period. The growth can be attributed to the growing number of patients globally. Also, the presence of a large number of hospitals providing advanced healthcare services. Hospitals have higher acceptance amongst the public, which is estimated to boost market growth. Additionally, hospitals often have dedicated stroke units and rehabilitation services, which are crucial for managing and recovering from cerebral artery syndrome.

Our in-depth analysis of the global market includes the following segments:

Treatment

  • Surgery
  • Medication

Surgery Type

  • Carotid Endarterectomy
  • Angioplasty
  • Bypass Surgery

Distribution Channel

  • Hospital
  • Specialty Clinic
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cerebral Artery Syndrome Treatment Industry - Regional Synopsis

North American Market Forecast

Cerebral artery syndrome treatment market in North America is expected to hold the largest share of 35% during the projected period. The growth can be attributed to the growing awareness among individuals regarding minimally invasive stroke treatment in the region. Also, the growing prevalence of atrial fibrillation is also driving the market growth in the region. As per a report, in the US, there are annually more than 454,000 hospital admissions with AFib as the major diagnosis. Each year, the illness is a contributing factor in over 158,000 deaths.

APAC Market Statistics

Asia Pacific region in cerebral artery syndrome treatment market is anticipated to hold the second-largest share of 26% during the projected period. The market is growing in the region due to the increasing initiatives taken by the government in the region to spread awareness about the condition. Also, growing investment for the betterment of healthcare infrastructure is propelling the market growth. As per a report, the region invested around USD 10.8 billion from 2008 to 2021 in the healthcare industry. Furthermore, growing R&D activities for the advent of new and advanced treatments are also accelerating the market growth of cerebral artery syndrome treatment in the region.

Research Nester
Cerebral Artery Syndrome Treatment Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Cerebral Artery Syndrome Treatment Landscape

top-features-companies
    • Bristol Myers Squibb
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Athersys, Inc.
    • Janssen Pharmaceuticals, Inc
    • Royal Philips
    • AstraZeneca plc

In-the-news

In The News

  • The FDA has granted Fast Track Designation for all three of the potential Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen), announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor, have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexiadevelopment program, which are all dosing patients. indications of milvexian, an investigational oral factor XIa (FXIa) inhibitor, to Bristol Myers Squibb (NYSE: BMY) in partnership with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen).
  • Following a Type B meeting with the U.S. Food & Drug Administration (FDA), Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine firm developing MultiStem® (invimestrocel) for critical care applications, announced proposed modifications to its MASTERS-2 clinical trial protocol. The meeting, which took place on March 21, 2023, covered the standard of care as well as Athersys' proposed modifications, which aim to establish primary and secondary endpoints that best reflect the company's belief of the full potential benefit of MultiStem treatment for patients with acute, moderate-to-severe ischemic stroke.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3463
  • Published Date: Jan 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing research and development activities, rising technological advancements in healthcare industry, and increasing awareness among the individuals are the major factors driving the growth of the cerebral artery syndrome treatment market.

The market size of cerebral artery syndrome treatment is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market are Bristol Myers Squibb, Athersys, Inc., Janssen Pharmaceuticals, Inc, Royal Philips, AstraZeneca plc, Daiichi Sankyo Company, Limited, LIFESCAPES Inc, Shionogi & Co., Ltd., Fujitsu, Takeda Pharmaceutical Co Ltd and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Cerebral Artery Syndrome Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying